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Abstract: We investigate the potential of an instrument combining time-
resolved spectrofluorometry and diffuse reflectance spectroscopy to 
measure structural and metabolic changes in cardiac tissue in vivo in a 16 
week post-myocardial infarction heart failure model in rats. In the scar 
region, we observed changes in the fluorescence signal that can be 
explained by increased collagen content, which is in good agreement with 
histology. In areas remote from the scar tissue, we measured changes in the 
fluorescence signal (p < 0.001) that cannot be explained by differences in 
collagen content and we attribute this to altered metabolism within the 
myocardium. A linear discriminant analysis algorithm was applied to the 
measurements to predict the tissue disease state. When we combine all 
measurements, our results reveal high diagnostic accuracy in the infarcted 
area (100%) and border zone (94.44%) as well as in remote regions from 
the scar (> 77%). Overall, our results demonstrate the potential of our 
instrument to characterize structural and metabolic changes in a failing heart 
in vivo without using exogenous labels. 
©2015 Optical Society of America 
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1. Introduction 
Diseases of the myocardium such as left ventricular hypertrophy and heart failure are 
frequently characterized by disturbances in mitochondrial metabolism and energetic 
dysfunction, and alterations in extracellular matrix and interstitial fibrosis. There is growing 
evidence that these structural and functional abnormalities contribute to progression of 
contractile dysfunction and electrical instability, underpinning the progression to pump failure 
and malignant ventricular arrhythmias, the two leading causes of morbidity and mortality in 
patients with left ventricular hypertrophy and heart failure. Currently the clinical tools 
available to evaluate and monitor myocardial metabolism and fibrosis have a number of 
limitations (e.g. FDG-PET, NMR spectroscopy, LGE-CMR) including low sensitivity and 
suboptimal spatial resolution in addition to practical barriers including relatively high cost, 
limited availability and the limitations for the frequency of repeated measures in the same 
individual. New technologies with greater sensitivity to detect and monitor changes in 
myocardial metabolism and progression of fibrosis are needed, which may help guide 
treatment selection and stratification at an earlier stage, and also cross correlate structural and 
functional changes to provide new insights into the pathophysiology of myocardial disease. 
Autofluorescence spectroscopy is a promising tool for characterization of biological 
tissues and shows potential for in vivo clinical diagnosis of diseased tissues and therefore 
optimization of therapeutic procedures [1]. It can exploit the photo-physical properties of 
endogenous fluorophores to probe the structural and functional properties of biological tissue 
and thus may provide label-free molecular contrast to report biochemical and metabolic 
information. The most common endogenous fluorophores in healthy cardiac tissue include 
enzyme co-factors nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FAD) [2–5], as well as extracellular matrix (ECM) components such as elastin 
#220276 - $15.00 USD Received 6 Aug 2014; revised 17 Oct 2014; accepted 21 Oct 2014; published 7 Jan 2015 
(C) 2015 OSA 1 Feb 2015 | Vol. 6, No. 2 | DOI:10.1364/BOE.6.000324 | BIOMEDICAL OPTICS EXPRESS 327 
and collagen [6,7]. In particular, the collagen matrix in healthy myocardium consists primarily 
of types I (85%) and III (11%) [8,9]. Changes in the fluorescence properties of NADH and 
flavins can report on changes in metabolic activity [10–13] and changes in collagen 
fluorescence can report changes in protein cross-linking and structural changes [14]. 
The application of optical spectroscopy to heart disease is still very limited and only a few 
in vivo studies have been reported. Many of these studies utilized reflectance spectroscopy to 
characterize the hemodynamic state of the heart by quantification of the tissue oxygenation 
and hemoglobin and myoglobin concentrations [15–18]. Other studies used steady-state 
autofluorescence intensity or emission spectroscopy to report cardiac tissue viability and 
metabolic state [7,19,20]. However, intensity measurements alone are sensitive to variations 
in excitation efficiency, fluorophore concentration and heterogeneous sample absorption and 
scattering and so are difficult to compare between samples and patients [21]. Spectrally-
resolved ratiometric measurements can provide quantitative readouts but their discrimination 
is limited by the broad overlapping fluorescence spectra of many tissue fluorophores [22]. 
Time-resolved fluorescence spectroscopy (TRFS) is an inherently ratiometric technique 
that aims to improve the specificity of fluorescence measurements by resolving the 
fluorescence intensity decay characteristics. Fluorescence lifetime (FL) can be sensitive to the 
molecular environment and therefore represents a direct approach to probe environmental 
parameters such as temperature [23], oxygenation [24], pH [25] or calcium concentration 
[26]. Furthermore, it is well suited to discriminate between fluorophores with overlapping 
emission spectra but different decay times [27]. TRFS has successfully been applied to tissue 
diagnosis in a wide range of applications, both ex vivo [28–31] and in vivo [32–35] and has 
shown potential for in vivo clinical diagnosis. 
In this study, we report a novel approach to cardiac investigation by applying TRFS to a 
rat 16 week post myocardial infarction heart failure (MI-HF) model that was previously well 
characterized in our laboratory [36–40]. The diagnosis of heart failure traditionally rested 
upon demonstration of impaired systolic function of the ventricle [8], although it is clear that 
heart failure can occur in the absence of reduced systolic function when reported as ejection 
fraction. Furthermore, characteristic structural, functional, electrical, metabolic and energetic 
remodeling follow a myocardial injury that precedes the overt symptoms associated with 
more advanced impairment of systolic function. Heart failure therapies aim to “reverse 
remodel” the deleterious changes and their effectiveness can be increased the earlier they are 
instigated to prevent progression [41]. This strategy employing a contrast agent (label) free 
method for in vivo characterization of cardiac tissue to identify the early alterations in the 
failing heart would represent a useful diagnostic advance to target early therapeutic 
intervention. 
We report the application of a compact optical fiber based instrument, which combines 
single point time-resolved spectrofluorometry and steady-state diffuse reflectance 
spectroscopy, to investigate the diagnostic potential of autofluorescence and reflectance in 
cardiac tissue. Although autofluorescence lifetime measurements have already been applied to 
studies of isolated cardiac cells [4,42] and in a number of other cardiovascular applications 
[21,43,44], its application to measurements of the whole heart remains limited [45]. To the 
best of our knowledge, this is the first in vivo application of TRFS to the study of cardiac 
tissue. 
2. Materials and methods 
2.1 16 week post-MI heart failure model 
All work involving animal use was carried out under protocols approved and regulated under 
the Animals (Scientific Procedures) Act 1986 (Project Licenses PPL 70/7399 and 70/7419). 
Adult male Sprague-Dawley rats (Charles River UK, Ltd.) weighing 250-300g underwent 
proximal left anterior descending (LAD) coronary ligation to induce chronic myocardial 
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infarction, as previously described [36]. Five percent isoflurane anesthesia was used for 
induction and once the animal was intubated and ventilated, anesthesia was maintained with 
2% isoflurane and opiate analgesia. Enrofloxacin (5 mg/kg) and 0.9% saline (10ml/kg) were 
administered preoperatively. A total of 6 animals, and their age-matched controls (AMC), 
were studied for in vivo epicardial fluorescence characteristics during a terminal procedure 16 
weeks post-surgical intervention, at which time a well-characterized heart failure phenotype is 
established [36–40]. The animal is anesthetized by placement in an anesthetic chamber with 
95%/5% O2 / isoflurane. A blunt 14G catheter is passed into the trachea under direct 
visualization and connected to a ventilator (Harvard Apparatus, USA). Anesthesia is 
maintained with 98%/2% O2 / isoflurane using tidal volume of approximately 2mL and a 
respiratory rate of approximately 90/min. Opiate analgesia is also given at appropriate dose 
for body weight. The heart and other internal organs are exposed via a laparotomy and 
sternotomy for spectroscopy measurements as described in section 2.5. In accordance with the 
reduction principle of the 3 Rs of animal research – replacement, reduction, refinement – the 
whole heart was explanted for cell isolation and an apical section taken for representative 
histology. 
2.2 Histology 
Cardiac tissue sampled for histology was washed in sterile PBS, fixed in 10% 
paraformaldehyde for 48 hours and then processed for paraffin embedding. 6µm thick 
sections were stained with picrosirius red (PSR) to demonstrate interstitial collagen content 
[46]. Whole sections were imaged using a 10x objective on a Zeiss Axio Observer inverted 
microscope with a fully motorized stage. Percentage interstitial fibrosis in each anatomical 
area of interest was quantified using Fiji image analysis software [47] by adjusting color 
thresholds to calculate the area of tissue positively stained with PSR. 
2.3 Measurement of fluorescence emission spectra of NADH, FAD and collagen type-I 
Solutions of β-NADH (N1161, Sigma-Aldrich, Germany) and FAD (F6625, Sigma-Aldrich, 
Germany) were prepared by diluting the respective powder in phosphate buffered saline 
(PBS) solution. Collagen type-I powder from rat tail was acquired from Sigma (C8897, 
Sigma-Aldrich, Germany) and used directly without further preparation. Measurements of the 
fluorescence emission spectra were carried out on a spectrofluorophotometer (RF-5301PC, 
Shimadzu, Japan) using 375 nm excitation light. Emission spectra were recorded from 400 to 
700 nm. A 390 nm long-pass filter was placed at the entrance slit of the monochromator to 
prevent contamination of the fluorescence signal by the excitation light. 
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2.4 Instrumentation 
 
Fig. 1. (A) Experimental layout of the single point fluorescence lifetime probe system and its 
optical fiber configuration at the excitation (proximal) and sample (distal) ends. Optical fiber 
cores are colored blue for excitation fibers, white for fibers delivering white light and 
collecting the diffuse reflected light and green for fibers collecting the fluorescence. (B) 
System mounted on a portable trolley for ease of deployment in clinical settings. (C) Distal end 
of the fiber-optic probe. 
The experiments described here were carried out using a custom-built optical fiber-based 
time-resolved spectrofluorometer designed to discriminate the fluorescence signals from 
endogenous fluorophores of interest, in particular, collagen, NADH and FAD. This system is 
configured as shown in Fig. 1(a). Excitation light is provided by two compact laser sources: a 
laser diode (LDH-P-C-375B, PicoQuant GmbH, Germany) providing 70 ps pulses at 372 nm 
with an average output power of 3.3 mW; and a second laser diode (LDH-P-C-440B, 
PicoQuant GmbH, Germany) generating 90 ps pulses at 438 nm, with 3.5 mW of average 
power. A single laser driver controls both lasers, allowing power control and adjustment of 
the repetition rate, which was set to 20 MHz. The laser beams are combined using a dichroic 
mirror and subsequently coupled into a custom-made optical fiber bundle (FiberTech Optica, 
Canada) consisting of three excitation fibers and fourteen detection fibers arranged in a 
hexagonal structure around the excitation fibers. There are also two extra fibers that are used 
for white light delivery and diffuse reflectance detection. Fluorescence light from the sample 
is collected by the detection fibers and directed to three spectrally resolved detection channels 
implemented using a set of dichroic mirrors and band-pass filters. When using 372 nm 
excitation, all three channels are active: the first channel collects light from 400 to 420 nm 
(CH1); the second channel collects light from 430 to 480 nm (CH2); the third channel accepts 
light from 500 to 550 nm (CH3). When using 438 nm excitation light, only the third (500-550 
nm) channel is active and, for convenience, this is referred as “channel 4” (CH4) hereafter. 
The detection band-pass filters used are shown in Fig. 2. Each detection channel has a photon-
counting photomultiplier (PMC-100-1, Becker-Hickl GmbH, Germany). The photomultipliers 
(PMT) are connected to a router (HRT-41, Becker-Hickl GmbH, Germany) that serializes the 
incoming signals for input to a time-correlated single photon counting (TCSPC) acquisition 
card (SPC-830, Becker-Hickl GmbH, Germany). The TCSPC system records the temporal 
fluorescence decay profile for each spectral channel. The instrument also comprises a white 
light source (HL-2000, Ocean Optics, USA) and a compact spectrometer (USB-2000 + , 
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Ocean Optics, USA) for diffuse reflectance measurements. The optical setup was assembled 
on a 30 × 45 cm2 breadboard (Thorlabs, USA), which was enclosed and mounted on a 
portable trolley for safe use and ease of deployment (see Fig. 1(b)). The system is fully 
controlled via a custom application written in LabVIEW (LabVIEW, National Instruments, 
USA). 
 
Fig. 2. Emission spectra of endogenous fluorophores of interest excited at 375 nm and plotted 
to show their relation to the spectral range of the detection channels of the fluorescence 
lifetime point probe system. Curves are normalized to their maximum amplitude. Data 
measured as described in section 2.3. 
2.5 Data collection 
In each heart, autofluorescence and diffuse reflectance data were collected from four regions 
of interest (ROI) (see Fig. 3): right ventricle (RV); left ventricle posterior wall (LV posterior), 
which represents the remaining viable myocardium in the presence of a large scar; left 
ventricle anterior wall/scar (LV anterior) and septum/scar border zone (border zone). In MI-
HF hearts, the border zone was defined as the non-infarcted tissue at the boundary of the 
infarcted area – as determined visually – on the anterior wall. For pairwise comparison, we 
defined border zone as the septum in the AMC. All measurements were realized with the fiber 
optic probe in gentle contact with the epicardial surface of the heart. Due to the natural 
movement of the heart, the pressure of the probe tip on the surface of heart will have varied 
slightly during each measurement and between consecutive measurements. We therefore 
ensured that the fluorescence data acquisition protocol would cover multiple (typically 3-6) 
heart beats so that any artefacts due to the heart motion during a measurement are averaged. 
To further average over possible artifacts associated with the placement of the probe, we also 
repeated each measurement, including removal and replacement of the probe tip, at each ROI. 
From each ROI, we acquired 3 sets of autofluorescence and diffuse reflectance data from each 
of 3 random positions within the ROI, i.e. 9 measurements in total. The integration time used 
in a single acquisition was 1 second for UV excitation, 1 second for blue excitation and 50 
milliseconds for diffuse reflectance measurements with white light illumination. 
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 Fig. 3. Diagram of the heart illustrating regions of interest (ROI) for our measurements: (A) 
anterior view; (B) posterior view. “RV” - right ventricle; “LV posterior” - left ventricle 
posterior wall; “LV anterior (scar)” - left ventricle anterior wall; and “border zone” - scar 
border zone or septum. 
3. Data analysis 
3.1 Spectral analysis of diffuse reflectance measurements 
Diffuse reflectance spectroscopy is a well-established technique that has previously been used 
to characterize tissue optical properties such as absorption coefficient, reduced scattering 
coefficient, hemoglobin and myoglobin concentrations and total blood oxygenation 
[15,48,49]. However, in this study we only intend to establish whether differences exist 
between healthy and damaged hearts. For this comparison, all acquired spectra were 
normalized to the signal of the diffuse reflectance from a white reference target (WS-1-SL, 
Labsphere, USA). All diffuse reflectance values are reported in units of absorbance, 
calculated as shown in Eq. (1), where A is the tissue absorbance, I is the measured spectrum 
and I0 is the calibrated spectrum of the white light source. 
 ( ) ( )( )10 0log
I
A
I
λλ λ
 
= −    
 (1) 
3.2 Spectral analysis of fluorescence measurements 
We calculated the fraction of the total autofluorescence signal in each spectral channel under 
UV excitation and the ratio of the autofluorescence signal between each of these channels. We 
excluded CH4 from ratio calculations as this is sensitive to any small day-to-day changes in 
fiber optic coupling efficiency and laser power differences between the 372 and 438 nm 
lasers. Because we aimed for the total photon counts to be approximately 1% of the laser 
repetition rate in each measurement, this required output power adjustment in different ROI 
and specimens. For each measurement, we collected a combined total of 19 lifetime and 
spectral parameters, as summarized in Table 3 in appendix. 
3.3 Fluorescence decay analysis 
Autofluorescence in biological tissue usually exhibits a complex profile due to the presence of 
multiple fluorophore species with overlapping spectra [1,22]. Such complex decay profiles are 
commonly described by a multi-exponential decay model 
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where τi and ai describe the decay time and pre-exponential factor of each component in the 
decay and C accounts for background light. Due to the limited number of photons in each 
spectral channel, we chose to fit a single exponential decay model to channel 1 data and a 
double exponential decay model to the remaining channels. From the decay parameters in Eq. 
(2) applied to a double exponential decay model, we can calculate the mean lifetime as 
defined in Eq. (3) 
 ( )1 21meanτ βτ β τ= + −  (3) 
where β refers to the contribution of the first component to the overall decay and is calculated 
as shown in Eq. (4). 
 1 1
1 1 2 2
a
a a
τβ
τ τ
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 (4) 
In order to be able to accurately fit a complex decay model to the data, it was necessary to 
measure the temporal instrument response function (IRF) of the system. Ideally, the 
measurement of the IRF includes the temporal broadening of the excitation pulse during its 
delivery through the excitation fiber and the broadening of the collected fluorescence through 
the detection fibers. We therefore measured the system response to reference fluorophores 
with known decay characteristics using 4′,6-Diamidino-2-phenylindole dihydrochloride 
(DAPI) (Sigma-Aldrich, USA) with 372 nm excitation in all detection channels and 
Erythrosin B (Sigma-Aldrich, USA) with 438 nm excitation. These reference dyes have 
lifetimes of approximately 200 ps and 90 ps, respectively, which are comparable to the pulse 
lengths of the lasers used. 
Autofluorescence lifetime data from each detection channel was analyzed employing the 
non-linear least squares fitting routine from MATLAB (lsqnonlin function, R2011b, The 
Mathworks Inc., USA) to minimize the goodness of fit chi-square value χ2, expressed as 
indicated in Eq. (5), 
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where n is the number of bins in the decay, I is the measured decay at each time delay and 
Imodel is the model decay function convolved with the instrument response function. The fitting 
model included the measured background offset and the measured after-pulsing probability of 
the detectors. To account for the temporal shift of the IRF with respect to the data caused by 
the distance between the tip of the probe and the reference dye solution, a temporal offset fit 
parameter was included in the fluorescence decay analysis. For all detection channels but 
channel 1, we extracted 4 lifetime parameters: β, τ1, τ2 and τmean. For channel 1, data were 
fitted to a single exponential decay model with lifetime τ. 
3.4 Linear discriminant analysis and principal component analysis 
To quantify differences between AMC and MI-HF hearts, within the corresponding ROI, we 
implemented a classification algorithm that is conceptually similar to the ones described in 
references [35,50,51], that employs principal component analysis (PCA) for feature selection 
followed by linear discriminant analysis (LDA) on the 5 most significant principal 
components (PC), using a ‘leave-one-out’ cross-validation approach that allows for each 
measurement to be classified as either AMC or MI-HF. A key point in our approach is that we 
focused on finding differences between equivalent regions of healthy and diseased hearts, 
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rather than distinguishing between different regions within the same heart. This is because, in 
a potential cardiovascular procedure guided by fluoroscopy, the position of the probe within 
the heart would be known but not the condition of different regions of the heart. As a first step 
to generate a diagnostic algorithm to discriminate healthy and diseased heart in specific ROI, 
each individual point measurement was used in this analysis providing a total of 54 
measurements per condition (9 measurements per ROI in 6 specimens). Receiver operator 
characteristic (ROC) curves were generated from the scores of each classification. The 
performance of each classifier was measured by the area under the ROC curve (AUC). 
3.5 Statistical analysis 
Data results are expressed as mean ± standard deviation (SD). Statistical analysis of different 
groups was computed using a two-tailed Student t-test. A p-value < 0.05 was considered to be 
significant. p-values for all ROI are presented in Table 4 in appendix. The discriminating 
power of each parameter for all ROI was calculated using the Cohen’s d coefficient (see Table 
5 in appendix). 
4. Results 
4.1 16 week post MI-HF model 
Cardiac occlusion of the left anterior descending artery (LAD) produced a large transmural 
MI and thus formation of scar tissue in the anterior wall of the left ventricle in all specimens 
(see Fig. 4). Compensatory hypertrophy of the remaining myocardium was confirmed by a 
significant increase (p < 0.05, n = 6) in heart to body weight ratio in MI-HF animals (3.40 ± 
0.60 g/kg) compared to AMC animals (2.84 ± 0.45 g/kg), in agreement with previous studies 
of this model [36]. Collagen content of the heart significantly increased in MI-HF animals 
compared to AMC (see Table 1 and Fig. 4). 
Table 1. Collagen content calculated from representative histology images. Statistical 
analysis between AMC and MI hearts was computed using a two-tailed Student t-test  
(n = 3). 
 Collagen content assessed by PSR staining (%) 
 AMC MI-HF p-value 
RV 4.50 ± 1.69 22.87 ± 4.17 0.0021 
LV posterior 6.53 ± 1.98 35.49 ± 9.09 0.0057 
Border zone 4.65 ± 0.73 28.30 ± 1.30 < 0.0001 
LV anterior 2.64 ± 0.17 74.19 ± 5.02 < 0.0001 
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 Fig. 4. Representative histology images from of AMC (left column) and MI-HF (right column) 
hearts. (A, E) RV; (B, F) LV posterior; (C, G) Border zone; (D, H) LV anterior 
4.2 Diffuse reflectance measurements 
Figure 5 presents the diffuse reflectance data for all ROI, indicating the tissue absorbance 
spectral profiles for AMC and MI-HF hearts, calculated as described in section 3.1. The data 
show an overall decrease in absorbance in MI-HF hearts, for all ROI. In AMC hearts, the 
maximum absorption peak at ~550 nm is consistent with the presence of cytochrome c. There 
is also a shoulder at ~580 nm, which can be attributed to the presence of the oxygenated 
forms of hemoglobin and myoglobin in the tissue, as expected in healthy AMC hearts (see 
Figs. 5 and 6). This feature is most pronounced in the RV, where there is a well-defined peak 
at ~580 nm. In MI-HF hearts, differences in the diffuse reflectance spectra were observed for 
infarcted (LV anterior) compared to non-infarcted (RV and LV posterior) regions. In scar 
tissue (LV anterior in MI hearts), the diffuse reflectance spectrum shows hallmark 
oxyhemoglobin/oxymyoglobin absorption features at ~540 and ~580 nm. We note that the 
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cytochrome c absorption peak is no longer visible in the mean spectrum for scar tissue, which 
is consistent with the low concentration of mitochondria expected owing to cell loss and 
replacement with scar. In regions remote to the MI, we observe a single peak in the 500 – 600 
nm band at ~550 nm consistent with cytochrome c accompanied by a smooth shoulder at 
~580 nm consistent with oxyhemoglobin/oxymyoglobin. 
 
Fig. 5. Diffuse reflectance spectra in (a) RV, (b) LV posterior, (c) Border zone, (d) LV 
anterior. Dashed lines indicate +/− 1 SD. 
 
Fig. 6. Absorbance spectra of key chromophores in cardiac tissue. The absorbance curves for 
human Hb and HbO2 were obtained from [52]. The absorbance curves for oxidized and 
reduced horse cytochrome C were obtained from [54]. The absorbance curves for horse Mb 
and MbO2 were obtained from [53]. The Hb and HbO2, Mb and MbO2 and reduced and 
oxidized cytochrome c pairs of curves were scaled in proportion with the largest of each curve 
being normalized to 1. 
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4.3 Autofluorescence spectral measurements 
Figure 7 shows the relative autofluorescence in each spectral channel for UV excitation by 
ROI (top row) and wavelength (bottom row). The results indicate an increased contribution of 
channel 1 to the total fluorescence signal in MI-HF hearts in all regions. This increase is most 
significant in LV anterior where the scar tissue was formed. Our histology (see Table 1 and 
Fig. 4) and previous histology [36] of this model has shown an increase in collagen type I in 
the scar, which, given its fluorescence emission spectrum (see Fig. 2), is consistent with the 
increase in fluorescence that we see in this channel. The increase in channel 1 contribution in 
sites remote to the MI, such as RV or LV posterior, also suggests an increase in collagen 
contribution in these regions, which is consistent with histology results and previous 
observations [7,36]. We observe an increase in the relative contribution of channel 2 in all 
regions, which is again consistent with an increase in collagen type I and its emission 
spectrum (see Fig. 2). As the total relative fluorescence signal must sum to one by definition, 
then the relative contribution of channel 3 to the total fluorescence signal therefore decreases 
for MI in all regions. The increase in collagen type I fluorescence is also apparent in the 
bottom row of Fig. 7 as a shift in the fluorescence emission towards shorter wavelengths for 
all ROI and this is most pronounced for LV anterior. 
 
Fig. 7. Relative contribution for each spectral detection channel for AMC and MI hearts, 
displayed by ROI (top row) and channel center wavelength (bottom row). Dashed lines in 
bottom row graphs identify the spectral range of each detection channel of the FL point probe 
system. 
4.4 Autofluorescence lifetime measurements 
Results of the autofluorescence lifetime data are plotted in Fig. 8. This data shows that MI-HF 
scar tissue (LV anterior) yields a longer mean autofluorescence lifetime compared to healthy 
LV myocardium in all detection channels. The increase in mean fluorescence lifetime in the 
LV anterior of MI-HF hearts is also reflected in all spectral channels in both the short (τ1) and 
long (τ2) decay components and as a decrease in the relative contribution of the short decay 
component (β). Changes in NADH or FAD fluorescence lifetimes may also be contributing to 
changes in the mean fluorescence lifetime but this is challenging to quantify in the presence of 
the large increase in collagen autofluorescence in the infarct scar (see Table 1). Statistically 
significant increases in mean fluorescence lifetime are also seen in all spectral channels for 
the border zone (see Table 4 in appendix), which we again attribute to an increase in type-I 
collagen in this region. In remotes sites from scar tissue, i.e. RV and LV posterior, we also 
observe statistically significant differences in decay profiles of channels 3 and 4. Particularly 
in channel 4, we see decreases in both τ1 and β for both regions in MI-HF compared to AMC 
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(Fig. 8 bottom row), which we believe cannot be explained by increases in collagen type-I 
concentration but might be explained by alterations in tissue metabolism in these regions. 
 
Fig. 8. Autofluorescence lifetime parameters for each spectral channel, displayed by ROI. 
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4.5 Discriminant analysis 
 
Fig. 9. Results from PCA of all spectroscopic parameters for each ROI shown as scatter plots 
of the scores of the first two PC for each ROI: a) RV, b) LV posterior, c) border zone and d) 
LV anterior. Different markers in the scatter plot identify data obtained from different 
specimens. Black lines show the decision lines produced by LDA analysis. 
In order to illustrate the capability of our system to discriminate between healthy and 
infarcted hearts in each ROI, we employed PCA followed by LDA as described in section 3.4. 
For purposes of comparison between methods, we applied the classification algorithm 
separately to the following groups: diffuse reflectance; fluorescence intensity; all fluorescence 
data (both lifetime and intensity); diffuse reflectance and fluorescence intensity; diffuse 
reflectance and all fluorescence data. Figure 9 shows the scores of the first two PC for each 
ROI using all fluorescence parameters and Table 2 summarizes the results of the 
discrimination algorithm applied to all groups of measurements. Classification results show 
that all methods are well-suited to discriminate between healthy and diseased hearts in scar 
tissue (LV anterior), where the AUC values calculated from ROC curves are close to 1 for all 
methods, and sensitivity and specificity range from 91 to 100% and 96 to 100%, respectively, 
demonstrating an excellent classification performance. In regions remote to the MI, i.e. RV 
and LV posterior, combined diffuse reflectance and fluorescence intensity parameters achieve 
the best classification, with measured AUC of 0.9886 and 0.8375, respectively. Particularly in 
the RV, sensitivity and specificity values are high (93 and 100%, respectively) for this 
method. It is also relevant to observe that for LV posterior the classification is poor in 
comparison to other regions, thus sensitivity and specificity in this region are generally lower 
(76 to 87% and 61 to 71%, respectively). In the border zone, the classification is more 
accurate when all fluorescence parameters (lifetime and intensity) are used - either in 
combination with diffuse reflectance (AUC = 0.9610) or alone (AUC = 0.9599) – in 
comparison to steady-state methods alone, i.e. diffuse reflectance or fluorescence intensity. 
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Table 2. Results of the PCA/LDA discrimination algorithm applied for each ROI using 
fluorescence and diffuse reflectance parameters and combinations of these parameters. 
  RV LV posterior Border zone 
LV 
anterior 
Diffuse reflectance 
Variance in data (%) 97.58 98.33 98.81 98.76 
Sensitivity (%) 86.67 80.00 82.22 100.00 
Specificity (%) 75.56 64.44 80.00 97.78 
Diagnostic accuracy (%) 81.11 72.22 81.11 98.89 
AUC 0.8993 0.8247 0.8978 0.9995 
Fluorescence intensity 
Variance in data (%) 100.00 100.00 100.00 100.00 
Sensitivity (%) 88.89 87.04 75.93 90.74 
Specificity (%) 92.59 61.11 100.00 100.00 
Diagnostic accuracy (%) 90.74 74.07 87.96 95.37 
AUC 0.9556 0.8169 0.9009 0.9966 
Fluorescence data 
(lifetime + intensity) 
Variance in data (%) 89.31 89.77 95.57 97.47 
Sensitivity (%) 92.59 75.93 87.04 98.15 
Specificity (%) 92.59 66.67 100.00 100.00 
Diagnostic accuracy (%) 92.59 71.30 93.52 99.08 
AUC 0.9722 0.8261 0.9599 1.0000 
Diffuse reflectance 
+ 
Fluorescence intensity 
 
Variance in data (%) 90.80 91.50 92.74 95.32 
Sensitivity (%) 93.33 84.44 88.89 100.00 
Specificity (%) 100.00 68.89 82.22 95.56 
Diagnostic accuracy (%) 96.67 76.67 85.56 97.78 
AUC 0.9886 0.8375 0.9235 1.0000 
Diffuse reflectance 
+ 
Fluorescence data 
(lifetime + intensity) 
 
Variance in data (%) 90.07 90.90 92.27 95.12 
Sensitivity (%) 88.89 84.44 91.11 100.00 
Specificity (%) 95.56 71.11 97.78 100.00 
Diagnostic accuracy (%) 92.22 77.78 94.44 100.00 
AUC 0.9768 0.8351 0.9610 1.0000 
5. Discussion 
In this work we have described the application of a compact instrument combining time-
resolved spectrofluorometry and diffuse reflectance spectroscopy to explore the potential of 
these label-free optical readouts in cardiac diagnosis using a rat 16-week MI heart failure 
model. Due to absorption and scattering of both the excitation light and emitted fluorescence, 
our instrument is most sensitive to fluorescence emitted near the surface of the heart, which 
can be a disadvantage in disease processes that vary with depth in the myocardium. However, 
it is known that myocardial infarction causes global alterations to the heart [55,56] and thus 
measurements from the epicardial surface of the heart represent a potential approach to probe 
its functional and structural state. In the future, incorporation of the fiber optic probe into 
cardiac catheters would facilitate these measurements from the endocardial surface during a 
minimally-invasive procedure. In addition, alternative probe geometries, e.g. with a different 
separation between illumination and detection fibers, could be investigated to adjust the depth 
probed. 
One of the major challenges in studies of cardiac tissue using autofluorescence or diffuse 
reflectance spectroscopy in vivo is related to the movement of the beating heart. The changing 
pressure between the probe and the heart surface will affect the blood content of the tissue in 
contact with the probe tip and this will influence the optical absorption. We chose a 
fluorescence measurement protocol with a duration spanning several cardiac cycles in order to 
average this effect. In addition, we performed three repeat measurements at each spatial 
location to achieve an average over multiple applications of the probe tip to the tissue surface. 
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Changes in the optical absorption caused by the mean pressure of the probe tip will 
influence the measured fluorescence intensity and diffuse reflectance spectrum most strongly. 
Ratios of the fluorescence signal between different spectral detection channels will also be 
affected due to the change in absorption between channels. The fluorescence lifetime data was 
acquired over a relatively narrow spectral band and is inherently ratiometric. Therefore, while 
the pressure of the probe tip may influence the mean depth that is probed, it should not greatly 
influence the fluorescence decay recorded provided that the tissue structure is homogenous 
over the volume probed. Overall, we achieved relatively small standard deviations on the 
fluorescence lifetime parameters obtained from AMC hearts which indicates that any 
variation in lifetime caused by variations in probe pressure is small. 
The diffuse reflectance spectrum is highly dependent on the absorption spectra of tissue 
chromophores. In cardiac tissue, the dominant chromophores are myoglobin, which is highly 
abundant in muscular tissue, and hemoglobin, which is present in red blood cells and is 
responsible for carrying oxygen to the cells. Myoglobin and hemoglobin exhibit similar 
absorption spectra (see Fig. 6) that are highly dependent on the tissue oxygenation [15,18]. In 
the presence of oxygen, the absorption spectrum of hemoglobin presents a double peak 
profile, with local maxima at ~540 nm and ~576 nm, as shown in Fig. 6. In contrast, in the 
absence of oxygen it exhibits a broader spectral profile with a single maximum peak at ~555 
nm. Reduced and oxidized myoglobin present similar spectra to hemoglobin with slightly red-
shifted absorption peaks. Other chromophores also contribute to the absorption spectra of 
heart tissue, such as mitochondrial cytochromes and cytochrome c in particular [15,51]. These 
play an important role in the regulation of the mitochondrial respiratory chain and therefore 
can provide readouts of the metabolic activity. The absorption spectrum of reduced 
cytochrome c has a well-defined peak at ~550 nm (see Fig. 6). 
Our diffuse reflectance data is in general agreement with previous studies [7,15]. We 
observed a decrease of absorption in MI relative to AMC hearts, which we attribute to 
reduced blood content and, as consequence, decrease in hemoglobin and myoglobin 
concentrations in the tissue. Our data also suggests high levels of tissue oxygenation in the 
scar tissue. The presence of this double peak profile in scar in the heart from 2 weeks post MI 
was previously reported by others [7], which they attributed to some recovery of tissue 
oxygenation. In our model the scar tissue is very thin (~700 μm) and so an alternative 
explanation may be that these peaks arise due to absorption of light by oxygenated blood 
within the LV cavity. A similar effect appears to be occurring for measurements of the RV in 
AMC hearts, although in this case, because healthy RV is metabolically more active than scar 
tissue, the signal also reflects the contribution of mitochondrial cytochromes, in particular 
cytochrome c, of which the reduced form has a strong absorption peak at around 550 nm (see 
Fig. 6). This high level of oxygenation is not observed in the RV in MI-HF hearts, which is 
consistent with the previously described [57] thickening of the RV wall in MI, as consequence 
of the remodeling process. In LV posterior and border zone in AMC hearts, we observed a 
single peak profile at ~550 nm - consistent with the presence of reduced cytochrome c - 
accompanied by a smooth shoulder at ~580 nm that reveals the contribution to the spectra of 
oxygenated hemoglobin and myoglobin. This shoulder is not as evident in LV posterior in MI 
hearts, which may be the result of the decrease in tissue oxygenation as consequence of the 
reduced blood content. Future work will involve the measurement of these optical properties 
with the aim of developing a model of light propagation in cardiac tissue. This could also 
include depth resolved diffuse reflectance studies with varying illumination and detection 
fiber separations in order to probe the complex nature of the cardiac signal. 
Our instrument recorded the autofluorescence emission into three spectral emission 
channels. For 372 nm excitation, the relative signal in these three channels is in agreement 
with the fluorescence emission spectra acquired by others [7]. In their work, Ti et al. 
measured the autofluorescence spectra - excited at 337 nm - of infarcted and non-infarcted 
regions at weeks 1 to 4 after the MI induction surgery. They observed a general increase in 
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autofluorescence intensity at week 1. Collagen-induced fluorescence was only visible 2 weeks 
post-MI with a pronounced emission peak at ~400 nm, which was also present at 4 weeks. In 
our model, we observe an increase in the relative fluorescence in channel 1, which suggests 
collagen proliferation not only in the infarction region (LV anterior) but also in sites remote to 
the MI reflecting interstitial fibrosis (Fig. 7), in agreement with previously published data on 
this model [58]. If we use the relative contribution of channel 1 to the total fluorescence signal 
as a quantitative measure of collagen content, we obtain a mean relative increase in collagen 
concentration of 93.0% in RV, 32.7% in LV posterior, 84.5% in border zone and 372% in LV 
anterior, which is positively correlated with qualitative observations of the histology data (r = 
0.9844, p < 0.05). This result demonstrates the sensitivity of our instrument to structural 
changes in cardiac tissue, both in infarcted and non-infarcted remodeled regions. 
We also observed an increase in the mean autofluorescence lifetime in scar tissue in all 
spectral channels. We believe this result can be explained by an increase in autofluorescence 
from collagen type-I when considering its broad emission spectrum (see Fig. 2) and its 
previously reported longer fluorescence lifetime. Previous studies of collagen fluorescence 
lifetime [59,60] have demonstrated that collagen decay characteristics are highly dependent 
not only of the excitation and emission spectra but also of the source of collagen itself. Using 
a previously described instrument [61] with excitation light at 375 nm, we have measured the 
fluorescence lifetime of collagen type-I from rat tail at the three emission wavelengths of 
interest - 410 nm, 455 nm and 525 nm - which correspond to the channel center wavelength of 
the single-point time-resolved spectrofluorometer used for this study. For these emission 
wavelengths we extracted mean lifetimes of 6.1, 5.8 and 5.9 ns, respectively. These results are 
within the range of what has been previously reported by others [59,60,62] and show that 
collagen yields a longer fluorescence lifetime compared to free and protein-bound NADH 
(0.4-0.5 ns and 1.0-3.0 ns respectively [63–65]) and FAD (3.0 ns to 0.3 ns respectively 
[65,66]). A smaller increase in mean fluorescence lifetime in MI-HF border zone relative to 
infarct is observed, which is consistent with a smaller rise in collagen content in this region 
compared to the main infarct scar. 
We aimed to measure changes in the NADH and FAD fluorescence lifetimes for all 
regions of the heart due to changes in tissue metabolism. However, their emission spectra 
overlap strongly with the broad emission spectrum of collagen type-I and it is challenging to 
quantify changes in NADH and FAD lifetime in tissue due to significant changes in collagen 
concentration and the corresponding changes in fluorescence lifetime. Based on previous 
work by others [64], we would expect to measure a decreased fluorescence lifetime from 
NADH in poorly oxygenated tissue, such as scar. However, the considerable increase in 
collagen and its longer fluorescence lifetime, along with extensive cellular loss, masks any 
change in NADH lifetime in the scar region. In regions that are remote from the scar, where 
the absolute increase in collagen is less pronounced, e.g. LV posterior and RV, it is reasonable 
to attribute the changes in fluorescence lifetime to changes in the fluorescence properties of 
intracellular fluorophores due to changes in energetics that are seen in heart failure. In 
particular, we see a statistically significant decrease in the short lifetime component τ1 excited 
at 438 nm in both RV and LV posterior viable myocardium in MI compared to AMC (p < 
0.05 and p < 0.001, respectively). We expect the fluorescence signal in this channel to be 
dominated by FAD autofluorescence and the short lifetime component has previously been 
linked to protein-bound FAD [13]. Given the long fluorescence lifetime of collagen compared 
to NADH and FAD, we do not see how these changes can be attributed to additional collagen 
in the MI heart. We therefore attribute them to tissue metabolic remodeling in the posterior 
wall of the LV MI heart that causes a change in autofluorescence signal due to the increased 
work load and altered metabolic state. This concept of alteration in the energetic state in the 
failing heart is well-established [67,68]. 
Changes in the metabolic state of tissue are also known to affect the optical redox ratio of 
NADH to FAD fluorescence in biological tissues [13,69–71]. In our instrument, the redox 
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ratio might, in principle, be estimated from the ratio of the fluorescence intensities measured 
in channels 2 and 3, which, in healthy cardiac tissue, is equivalent to the ratio 
[NADH]/(α[NADH] + β[FAD]), where α and β represent the relative contributions of NADH 
and FAD respectively to channel 3 intensity under 372 nm excitation. However, although we 
were expecting to observe changes in the redox ratio in MI-HF hearts due to energetic 
alterations, as discussed above, the autofluorescence signals of channels 2 and 3 are 
“contaminated” by collagen type I autofluorescence, making it challenging to discern the 
origin of changes in the measurement, which could be structural or metabolic alterations of 
the tissue. This emphasizes the importance of any information concerning metabolic 
alterations in the tissue that can be provided by fluorescence decay measurements that are not 
masked by structural changes, e.g. associated with collagen. Our measurements of the short 
lifetime component associated with FAD autofluorescence, which has been previously 
associated with the protein-bound state of the molecule, are not confounded by changes in 
collagen autofluorescence and appear to indicate changes in the energetic state of the tissue. 
To summarize, our results suggest that the single-point time-resolved spectrofluorometer can 
read out structural and energetic alterations in the tissue. Structural alterations associated with 
fibrosis were indicated by both steady-state autofluorescence parameters (i.e. shift in the 
autofluorescence emission spectra towards shorter wavelengths) and time-resolved parameters 
(i.e. increase in the mean autofluorescence lifetime in all spectral channels). We note that this 
increase in collagen could also be detected using other approaches such as SHG microscopy 
[72]. However, the change in the FAD short component lifetime, which we provisionally 
associate with altered metabolism in the failing heart, provides information that is only 
available through time-resolved autofluorescence data. 
To validate the potential of our instrument to distinguish healthy from diseased cardiac 
tissue, we implemented a discrimination algorithm, employing PCA followed by LDA, on a 
leave-one-out cross-validation approach. For consistency between methods, the five most 
significant PC were used as predictor variables in the discrimination matrix for all methods 
and for all combinations of methods. Our results, presented in Table 2, show that all methods 
provide excellent discriminant capabilities when applied directly to the infarcted region. This 
is expected as in this model the scar is completed and mature and could easily be determined 
visually due to its coloration. However, it is interesting to note that the best discriminant 
parameters in LV anterior - calculated through the Cohen’s d coefficient (see Table 5 in 
appendix) - are lifetime related parameters, which is consistent with the higher diagnostic 
accuracy calculated for classifications that include these parameters. In the border zone 
region, the accuracy of the classification decreased compared to that achieved for 
classification of scar. Our results show that steady-state methods alone provide a lower 
accuracy than when combined with time-resolved parameters. Classification results for LV 
anterior and border zone suggest that lifetime parameters are more sensitive to increase in 
collagen content - and therefore structural changes in the tissue - for the excitation and 
detection wavelengths used in this study. In sites remote to the MI, our results show that 
intensity based parameters provide better discrimination between healthy and diseased 
myocardium compared to lifetime based parameters. This is particularly evident in RV (see 
Table 5 in appendix) and explains the classification results in this ROI, which show that 
fluorescence intensity parameters in combination with diffuse reflectance provide the most 
accurate tissue state classification. In LV posterior myocardium, it is interesting to observe 
that the best discrimination parameter is the short lifetime component extracted from the 
channel 4 fluorescence decay. As discussed above, we believe that the observed change in this 
parameter does not reflect an increase in collagen content, but may explain the energetic 
impairment in the myocardium in post-MI heart failure. It is also relevant to point out that the 
best discriminant parameters given by the Cohen’s d statistics in this ROI occur in channels 2, 
3 and 4 - which include the emission wavelengths of NADH and FAD - and can also be 
associated to alterations in energetic state. As collagen proliferation is still observed through 
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histology, we believe that the autofluorescence signal collected in this anatomical area is a 
result of both structural and metabolic changes. 
6. Conclusions 
We have presented an exploration of in vivo time-resolved spectrofluorometry and diffuse 
reflectance spectroscopy with a view to developing a new cardiac diagnostic tool. We have 
demonstrated the potential of our instrument to report structural and metabolic changes in 
cardiac tissue in a 16 week post-MI heart failure model in rats, not only in the anatomical area 
of infarction but, more excitingly, also in remodeled myocardium remote from the scar where 
we report, for the first time, changes in the autofluorescence signal that we provisionally 
attribute to metabolic alterations within the myocardium. Using a PCA-based discrimination 
algorithm we were also able to accurately distinguish healthy from diseased myocardium, 
even in sites remote to the infarction where changes in tissue properties are more subtle. 
Future work will characterize the autofluorescence lifetime signature at earlier time-points 
during the development of heart failure following MI, particularly before extensive collagen 
proliferation occurs. Once the autofluorescence signatures that accompany the structural, 
functional and metabolic aberrations in other cardiac disease states have been further 
characterized, this approach could be applied either during open-chest procedures or via 
incorporation of fiber optic probe into coronary angiography or electrophysiology catheters. 
Catheter-based autofluorescence measurements have the potential to be relatively low cost 
compared to PET or functional MRI and could be performed without the need for contrast 
agents, e.g. during angioscopy or between catheter-based ablation procedures, to provide 
feedback to the clinician. Autofluorescence measurements also have the potential to be used 
during open-chest surgery while the patient is still connected to a heart and lung machine. 
Appendix 
Table 3. List of spectroscopic parameters extracted from a single fluorescence lifetime 
measurement 
Channel Index Description 
Channel 1 τ Fluorescence lifetime 
Channel 2 τmean Weighted mean fluorescence lifetime 
 τ1 Short lifetime component 
 τ2 Long lifetime component 
 β Contribution of the first component 
Channel 3 τmean Weighted mean fluorescence lifetime 
 τ1 Short lifetime component 
 τ2 Long lifetime component 
 β Contribution of the first component 
Channel 4 τmean Weighted mean fluorescence lifetime 
 τ1 Short lifetime component 
 τ2 Long lifetime component 
 β Contribution of the first component 
 CH1 R Relative fluorescence in channel 1 
 CH2 R Relative fluorescence in channel 2 
 CH3 R Relative fluorescence in channel 3 
 CH1 I/CH2 I Fluorescence intensity in CH 1 / Fluorescence intensity in CH2 
 CH2 I/CH3 I Fluorescence intensity in CH 2 / Fluorescence intensity in CH3 
 CH1 I/CH3 I Fluorescence intensity in CH 1 / Fluorescence intensity in CH3 
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 Table 4. P-value results from two-tailed Student’s t-test, for all ROI. A p-value < 0.05 was 
considered to be significant. 
 Index RV LV posterior Border 
zone 
LV anterior 
Channel 1 τ 0.3407 0.0748 0.0078 < 0.0001 
Channel 2 τmean 0.7680 0.1343 0.0115 < 0.0001 
 τ1 0.2271 0.3131 0.0214 < 0.0001 
 τ2 0.2110 0.0054 0.0038 < 0.0001 
 β 0.4198 0.0728 0.0706 < 0.0001 
Channel 3 τmean 0.6285 0.3961 0.0167 < 0.0001 
 τ1 0.1669 0.0753 0.0349 0.0003 
 τ2 0.2748 0.0185 0.0051 < 0.0001 
 β 0.4914 0.0440 0.2795 < 0.0001 
Channel 4 τmean 0.7391 0.5037 0.0107 < 0.0001 
 τ1 0.0196 0.0002 0.3874 0.0324 
 τ2 0.3773 0.5405 0.0099 < 0.0001 
 β 0.0123 0.0180 0.2994 0.0004 
 CH1 R 0.0021 0.0451 0.0172 < 0.0001 
 CH2 R 0.0055 0.0041 0.0162 < 0.0001 
 CH3 R 0.0016 0.0025 0.0073 < 0.0001 
 CH1 I/ CH2 I 0.0007 0.0212 0.0040 < 0.0001 
 CH2 I/ CH3 I 0.0034 0.0013 0.0072 < 0.0001 
 CH1 I/ CH3 I 0.0061 0.0330 0.0271 < 0.0001 
Cohen’s d 
Cohen's d is an appropriate effect size measurement for the comparison between two means. 
It indicates the standardized difference between two means, and expresses this difference in 
standard deviation units. The Cohen’s d coefficient can be defined in terms of population 
means μ and standard deviations s, as shown below: 
 1 2d
μ μ
σ
−
=  (A1) 
where 
 
2 2
1 2
2
s s
σ
+
=  (A2) 
As an effect size measure, a larger Cohen’s d represents a greater differentiation between two 
groups. Thus, it is traditionally presented as complementary to the report of results from a 
statistical significance test. Whereas the latter is used to suggest whether a difference exists 
between two groups, the Cohen’s d reports the magnitude of this difference. 
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Table 5. Fluorescence parameters ranked by Cohen’s d coefficient. 
RV LV posterior Border zone LV anterior 
Parameter Cohen's 
d 
Parameter Cohen's 
d 
Parameter Cohen's 
d 
Parameter Cohen's 
d 
CH1 I/CH2 I 2.8036 CH4 τ1 3.2132 CH2 τ2 2.1595 CH2 τ2 13.4927 
CH3 R 2.4672 CH2 I/CH3 I 2.5538 CH1 I/CH2 I 2.1435 CH3 τ2 11.2469 
CH1 R 2.3745 CH3 R 2.3114 CH3 τ2 2.0612 CH2 τ 10.9477 
CH2 I/CH3 I 2.2016 CH2 R 2.1350 CH2 I/CH3 I 1.9414 CH4 τ 9.7707 
CH1 I/CH3 I 1.9966 CH2 τ2 2.0432 CH3 R 1.9385 CH3 τ 9.5738 
CH2 R 2.0333 CH4 β 1.6309 CH1 τ 1.9126 CH4 τ2 9.1585 
CH4 β 1.7603 CH3 τ2 1.6215 CH4 τ2 1.8327 CH2 β 8.8652 
CH4 τ1 1.6019 CH1 I/CH2 I 1.5762 CH4 τ 1.8066 CH3 R 7.6861 
CH3 τ1 0.8607 CH1 I/CH3 I 1.4274 CH2 τ 1.7817 CH1 τ 7.4315 
CH2 τ2 0.7717 CH3 β 1.3301 CH2 I 1.6671 CH2 I/CH3 I 6.8895 
CH2 τ1 0.7430 CH1 R 1.3214 CH3 τ 1.6558 CH3 β 6.0840 
CH3 τ2 0.6670 CH2 β 1.1575 CH1 R 1.6471 CH1 R 5.8111 
CH1 τ 0.5776 CH1 τ 1.1483 CH2 τ1 1.5728 CH2 R 5.5292 
CH4 τ2 0.5334 CH3 τ1 1.1457 CH1 I/CH3 I 1.4936 CH1 I/CH2 I 5.4861 
CH2 β 0.4857 CH2 τ 0.9408 CH3 τ1 1.4084 CH1 I/CH3 I 4.7944 
CH3 β 0.4124 CH2 τ1 0.6133 CH2 β 1.1683 CH2 τ1 4.1752 
CH3 τ 0.2881 CH3 τ 0.5119 CH3 β 0.6602 CH3 τ1 3.1062 
CH4 τ 0.1977 CH4 τ 0.4005 CH4 β 0.6318 CH4 β 2.9804 
CH2 τ 0.1750 CH4 τ2 0.3659 CH4 τ1 0.5217 CH4 τ1 1.4332 
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